Profitability • Vir Biotechnology
VIR
Vir Biotechnology Inc., founded in 2016, is a clinical-stage biopharmaceutical company that develops innovative immunologic therapies to combat serious infectious diseases such as COVID-19 and hepatitis B. Operating within the Health Care sector, the company emphasizes leveraging advanced scientific research to meet significant unmet medical needs. Vir Biotechnology generates revenue primarily through strategic collaborations, licensing agreements, and milestone-based payments tied to its therapeutic candidates. Its business model is centered on partnering with global pharmaceutical companies and government agencies to bring novel treatments from development to commercialization. The company’s leading product candidate is VIR-7831 (sotrovimab), a monoclonal antibody that received emergency use authorization for COVID-19 treatment, forming a critical part of its portfolio. In addition, Vir is actively expanding its pipeline with candidates targeting hepatitis B and influenza, supported by collaborations with major pharma partners. Its integrated approach combines rigorous clinical development with advanced computational methods to enhance the safety and efficacy profiles of its treatments. Vir Biotechnology is led by CEO George Scangos, a veteran in the biotechnology industry with extensive experience in steering innovative drug development initiatives. Alongside him, a team of seasoned executives in research and commercialization drives the company’s strategic clinical operations and partnerships. Vir holds a competitive stature among biotech firms focused on infectious diseases, with its innovative product pipeline contributing to a market capitalization exceeding $3 billion. Strategic alliances and early successes, especially in COVID-19 therapeutics, have positioned the company as an influential player in a niche market with significant growth potential. Looking forward, Vir Biotechnology plans to advance multiple candidates through clinical trials while exploring new indications and expanding its portfolio to address broader infectious disease challenges. The company is focused on achieving key regulatory milestones, deepening its strategic partnerships, and leveraging its innovative platform to drive long-term revenue growth.
100%
Gross Margin
Gross margin measures the amount of revenue that remains after subtracting costs directly associated with production.
—
EBITDA Margin
The EBITDA margin is a measure of a company's operating profit desconsidering D&A costs as a percentage of its revenue.
—
EBIT Margin
The EBIT margin is a measure of a company's operating profit considering D&A costs as a percentage of its revenue.
—
Net Margin
The net profit margin, or simply net margin, measures how much net income or profit is generated as a percentage of revenue. It is the ratio of net profits to revenues for a company or business segment.
0%
D&A/EBITDA
Many companies have a high D&A in relation to the company's operating profit (EBITDA) and although this indicator does not have an effective cash effect, it ends up influencing the accounting net income, so analyzing this relationship can help to understand when D&A has a relevant impact to the company's results.
665,1%
R&D/Revenue
Shows the amount spent on investments in research and development in relation to the Net Revenue for the period. The company can use these investments to try to increase its revenue in the future.
13,1%
Capex/Revenue
Shows the amount spent on investments in Capex in relation to Net Revenue for the period. The company can use these investments to try to increase its revenue in the future.
77%
Capex/D&A
Indicates a comparison between investments in fixed/intangible assets and the depreciation and amortization of some company assets. It serves to let managers know that the company's assets are devaluing periodically, and whether CAPEX has followed the same pace or not.
-2,3%
Capex/OCF
It shows the percentage of operating cash flow that the company uses in Capex (investments in fixed and intangible assets). When your result is greater than 100%, it demonstrates that there are expenses greater than what the company produces in its operations.
—
SBC/OCF
It demonstrates the percentage cost of Stock-Based Compensation compared to the company's operating cash flow. In some companies, the OCF is positive because of the SBC, which can lead to an incorrect cash flow analysis.
11,7%
% PPE
If the company has a lot of D&A, it helps to see if most of it tends to come from fixed assets. The account can include machinery, equipment, vehicles, buildings, land, office equipment, and furnishings, among other things.
1,7%
% Goodwill
If the company has a lot of D&A, it helps to see if most of it tends to come from Goodwill, that is an intangible asset that accounts for the excess purchase price of another company.
—
ROE
Return on equity (ROE) is the measure of a company's net income divided by its shareholders' equity and is a gauge of a corporation's profitability and how efficiently it generates those profits.
—
ROIC
Return on invested capital (ROIC) is a calculation used to assess a company's efficiency in allocating capital to profitable investments. The formula for calculating ROIC involves dividing Net Income by the average of invested capital.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!